Busy schedule ahead for the Investor Relations Team.
The company expects to report top-line results from the ROCELLA phase IIb trial of ‘1972 in osteoarthritis in H2.
Within the fibrosis portfolio, the company expects to report top-line results from PINTA ph II trial with ‘1205 in IPF and NOVESA ph IIa data of ‘1690 in SSc.
September 07, 2020
Kepler Cheuvreux Autumn Conference
September 09, 2020
Citi Biopharma Conference
September 10, 2020
Knowledge for Growth
September 14, 2020
MS Global Healthcare Conference
September 15, 2020
Cantor Global Healthcare Conference
September 17, 2020
BofA Virtual London September Global Healthcare Conference
September 24, 2020
Bernstein 17th Annual SDC
September 29, 2020
J.P. Morgan CEO call 2020
October 01, 2020
Stifel – Immunology & Inflammation Summit
November 17, 2020
Stifel Healthcare Conference